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Abstract: Insulin resistance (IR) and microRNAs (miRNAs), which regulate cell-to-cell communication
between hepatocytes and hepatic stellate cells (HSCs), may intertwine in nonalcoholic fatty liver disease
(NAFLD) pathogenesis. The aim of this study was to evaluate whether epigenetics and environmental
factors interact to promote progressive NAFLD during IR. We examined the miRNA signature in
insulin receptor haploinsufficient (InsR+/−) and wild-type (wt) HSCs by RNAseq (n = 4 per group).
Then, we evaluated their impact in an IR-NASH (nonalcoholic steatohepatitis) model (InsR+/−mice
fed standard or methionine choline deficient (MCD) diet, n= 10 per group) and in vitro. InsR+/−HSCs
displayed 36 differentially expressed miRNAs (p < 0.05 vs. wt), whose expression was then analyzed
in the liver of InsR+/−mice fed an MCD diet. We found that miR-101-3p negatively associated with
both InsR+/− genotype and MCD (p < 0.05) and the histological spectrum of liver damage (p < 0.01).
miR-101-3p was reduced in InsR+/− hepatocytes and HSCs and even more in InsR+/− cells exposed
to insulin (0.33 µM) and fatty acids (0.25 mM), resembling the IR-NASH model. Conversely, insulin
induced miR-101-3p expression in wt cells but not in InsR+/− ones (p < 0.05). In conclusion, IR
combined with diet-induced liver injury favors miR-101-3p downregulation, which may promote
progressive NAFLD through HSC and hepatocyte transdifferentiation and proliferation.
Keywords: NAFLD; fibrosis; HCC; hepatic stellate cells; miR-101-3p
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) represents the leading cause of progressive liver
disorders worldwide, affecting between 20% to 40% of the adult population [1]. NAFLD is defined
by increased hepatic fat accumulation not explained by alcohol abuse, and it encompasses a wide
spectrum of liver injuries, ranging from simple steatosis (>5% of liver weight) to its inflammatory
form nonalcoholic steatohepatitis (NASH). NASH may be complicated by the presence of fibrosis and,
eventually, it may progress to cirrhosis and hepatocellular carcinoma (HCC) [2,3]. NAFLD has a strong
inherited component, and variants in proteins regulating hepatocellular lipid handling, including
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patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2
(TM6SF2), membrane bound O-acyltransferase domain-containing 7 (MBOAT7), predispose to the
disease development and progression to NASH and fibrosis [4]. Dietary habits such as excessive
caloric intake, fructose consumption, and physical inactivity represent other risk factors for NAFLD
development [5]. In addition, its pathogenesis is closely intertwined with excessive adiposity, insulin
resistance (IR), and metabolic syndrome [6].
IR even correlates with the severity of liver fibrosis [7], the main determinant of NAFLD
prognosis [5]. Indeed, fibrosis has been observed in diabetic patients with NAFLD even independently
of NASH [6], and genetic variants that impair insulin receptor (InsR) signaling favor fibrosis
development in NAFLD patients [8]. The mechanism whereby IR aggravates fibrosis may be related to
reduced extracellular matrix (ECM) degradation and to the induction of proteins involved in collagen
crosslinking [9].
A new perspective of NAFLD pathogenesis and management is provided by epigenetics,
which modulate transcriptome in response to environmental cues. In particular, microRNAs (miRNAs)
are short non-protein coding, single-strand RNAs of 19–22 nucleotides that regulate gene expression
and cell-to-cell communication as it occurs between hepatocytes and hepatic stellate cells (HSCs)
during fibrogenesis [10]. Alteration of miRNA expression in response to genetic/epigenetic factors or
environmental conditions may contribute to steatosis onset and NAFLD progression to fibrosis and
cancer [11], mirroring the histological features and the molecular events occurring in NAFLD [12].
Thus, they could be exploited as attractive candidate biomarkers for an accurate profiling of the
different stages of liver injury, enabling early and non-invasive diagnosis and the clinical monitoring
of the disease progression.
Therefore, we aimed to explore the mechanisms through which epigenetics and environmental
factors interact to promote progressive NAFLD in the context of IR. To this purpose, we first assessed
which miRNAs were deregulated by IR in HSCs whose activation represents the hallmark of liver fibrosis.
Secondly, we evaluated whether the miRNAs differentially expressed in insulin resistant HSCs could
impact on NAFLD-related fibrosis by using an experimental model of IR-NASH. Thus, to investigate
the independent contribution of IR and NASH that is usually intertwined in patients on miRNAs
expression, IR was induced in mice by haploinsufficiency for InsR (InsR+/−) [13–15], which determines
an impairment of hepatic insulin signaling recapitulating that has been observed in NAFLD patients [8].
Conversely, to model fibrogenic NASH, we exploited the methionine choline deficient (MCD) diet,
which impairs phospholipid metabolism without altering IR [16]. Finally, we tested the expression of
the candidate miRNAs in immortalized human hepatoma cells (HepG2) and in HSCs (LX-2) in the
presence or absence of miRNA mimics. Here, we showed that miR-101-3p was downregulated in
InsR+/−HSCs and hepatocytes, its expression was reduced even in total livers of insulin resistant mice,
and it was associated with all stages of liver disease.
Consistently with these results, target prediction analysis revealed that miR-101-3p is involved in
insulin signaling, lipid metabolism, cell proliferation, fibrogenesis, and cancer susceptibility, possibly
representing a molecular signature in NAFLD during IR. Furthermore, miR-101-3p overexpression
in HepG2 and LX-2 reduced proliferation, migration, and invasiveness, regulating pro-fibrotic and
pro-carcinogenic markers.
2. Materials and Methods
2.1. Experimental Models
C57Bl/6 mice (Charles River, Calco, Italy) were housed at constant room temperature (23 ◦C)
under 12-hour light/dark cycles with ad libitum access to water in compliance with the Principles of
Laboratory Animal Care (NIH publication 86-23). InsR+/−mice on C57Bl/6 background were kindly
provided by Prof. Accili D., Columbia University, NY, USA [13]. Genotyping was performed using
genomic DNA extracted from mouse tail [15]. Primers are listed in Table S1.
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To induce NASH, wild-type (wt) and InsR+/−male mice (more susceptible to liver damage and
fibrosis) were fed either MCD (14.8% protein, 12.4% fat, and 72.8% carbohydrate, Test Diet, London,
United Kingdom) or regular chow (15.1% protein, 12.4% fat, and 72.4% carbohydrate, Test Diet, London,
United Kingdom), from 6 weeks of age, for 6 weeks. We tested two timelines of MCD administration
(3 and 6 weeks) in preliminary experiments by using a powder MCD, which induced a more severe
liver damage compared to MCD pellet and early loss of 20% of body weight. Thus, to not run into
ethical issues, we did not expose animals to a prolonged MCD regimen (8 weeks) but we selected the
adequate timeline (6 weeks) that could be representative of both NASH and fibrosis. Experiments
were conducted in 10 mice per group. Body weight was recorded weekly throughout the experiments.
Before sacrifice, mice were fasted for 16 h and the interventions were done during the light cycle.
All animal experiments were performed according to the experimental protocol approved by University
of Milan and Italian Ministry of Health Review Boards (protocol 8/14). The biochemical and histological
features of SD and MCD mice are provided in Table S2. Detailed methods and reagents are presented
in the Supplementary Materials and Methods.
2.2. Isolation of Hepatic Stellate Cells
The detailed protocol and data analysis approach are described in the Supplementary Materials
and Methods.
2.3. Histology and Immunohistochemistry
The detailed protocol and data analysis approach are described in the Supplementary Materials
and Methods.
2.4. Transcriptome Analysis on Hepatic Stellate Cells (Discovery)
Isolated HSCs were cultured on plastic for three passages. Total RNA was isolated using miRNeasy
micro-kit (Qiagen, Hulsterweg, Germany). The purity and the concentration of RNA samples were
determined with the NanoDrop ND-1000 spectrophotometer (Thermofisher Scientific, Carlsbad, USA).
The integrity of the RNA was assessed by electrophoresis and by RIN evaluation through Agilent 2100
Bioanalyzer (Thermofisher Scientific, Carlsbad, USA). RNA sequencing was performed in paired-end
mode with a read length of 150 nt using the Illumina HiSeq 4000 (Novogene, Hong Kong, China).
RNAseq mapping descriptive statistics, the detailed protocol, and data analysis approach are described
in the Supplemental Materials and Methods and in Table S3.
2.5. Quantitative Real Time PCR (qRT-PCR) Validation of miRNAs in Total Livers
Custom Taqman Array Plates and qRT-PCR were used to confirm the expression profiles of
miRNAs obtained from the RNAseq data and their potential biological relevance to disease pathogenesis.
Total RNA was isolated using miRNeasy mini-kit (Qiagen, Hulsterweg, Germany) from total liver of
InsR+/− and wt mice, fed a standard or MCD diet. Then, miRNAs were reverse transcribed using
Taqman Advanced miRNA cDNA synthesis kit (Thermofisher Scientific, Carlsbad, U.S.A.), according
to the manufacturer’s protocol. The relative gene expression was determined using QuantStudio 3
Real-Time PCR System and Taqman Fast Advanced Master Mix (Thermofisher Scientific, Carlsbad, USA).
All miRNA expression was normalized by using a pool of endogenous housekeeping (hsa-miR-361-5p,
hsa-miR-186-5p, hsa-miR-26a-5p, hsa-miR-191-5p, hsa-miR-451-5p, and hsa-miR-423-5p) and shown as
the fold change, according to the 2−∆∆Ct method. Primers used are listed in Table S4.
2.6. Bioinformatic Resources
To clarify biological functions of the differential expressed miRNAs identified in HSCs and to
investigate the pathways related to the miRNA-selected target genes, gene ontology (GO) enrichment
Nutrients 2019, 11, 2597 4 of 19
analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed by DAVID
(https://david.ncifcrf.gov, version 6.8) and Enrichr (http://amp.pharm.mssm.edu/Enrichr/enrich).
The miRNA-RNA target interaction analysis was evaluated using prediction software, including
TargetScan (www.targetscan.org/) and miRanda (www.microrna.org/). GO analysis was also performed
to explore the functional roles of miRNAs in terms of biological processes and molecular functions,
and KEGG was used to determine the target genes in different biological pathways.
2.7. In Vitro Treatments
HepG2 (obtained from ATCC, ATCC-HB-8065) and LX-2 (Sigma-Aldrich, St. Louis, United States,
SCC064) cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-ThermoFisher
Scientific Waltham, United States), supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml
penicillin, and 0.1 mg/ml streptomycin, and incubated in a 5% CO2 humidified incubator at 37 ◦C.
HepG2 and LX-2 were exposed to 0.33 µM insulin (Insuman Rapid, Sanofi Aventis) for 6 h.
In another experimental setting, hsa-miR-101-3p mimic (# 4464066) or miR-1 positive control
(# 4464062) (mirVana miRNA mimic, ThermoFisher Scientific) were administered at a final concentration
of 25 nM in complete medium without antibiotics and 0.5% bovine serum albumin (BSA). The cells were
washed with PBS and then transiently transfected with 25 nM mir-101 mimic or miR-1 positive control
using Lipofectamine 3000 (Thermo-fisher Scientific) according to the manufacturer’s instructions.
We tested two different miRNA mimic concentrations (25 and 50 nM) and reached a great efficiency of
transfection with both concentrations. Thus, we chose the lower concentration (25 nM), which has been
frequently used in various studies [17–19]. At least three independent experiments were performed.
2.8. Cell Proliferation Assay
HepG2 and LX-2 cells are broadly used to study hepatic metabolism and related disorders as
models in vitro. To explore the impact of miR-101-3p on hepatic fibrosis and cell proliferation, we used
immortalized cell lines because of their higher rate of proliferation and their ability to maintain
cell-specific features.
HepG2 and LX-2 cells (2500 cells/well) were seeded in 96-well plate in quadruplicate and incubated
under normal culture conditions for 24 h prior to transfection. Cell proliferation was measured using
the CellTiter96-Aqueous One Solution Cell Proliferation Assay (MTS) kit (Promega Corporation,
Fitchburg, USA) according to the manufacturer’s instructions. MTS reagent (20 µL/well) was added to
the cells followed by incubation for 4 h in 5% CO2 humidified incubator at 37 ◦C, and the absorbance
was measured at 490 nm, at 0, 24, 48, and 74 h after transfection. At least three independent experiments
were carried out.
2.9. Wound Healing Assay In Vitro
HepG2 and LX-2 cells were seeded in 6-well plate (800,000 cells/well) in duplicate and incubated
for 24 h prior to transfection with mir-101 mimic or miR-1 positive control (25 nM). When the cells
reached ~90% confluency, a 20 µL pipette tip was used to scrap across the confluent layer, followed
by gently washing with PBS three times and then by the addition of culture medium containing 10%
fetal bovine serum (FBS). An area surrounded the wound was photographically monitored for 2 days
consecutively. Wound healing ability was determined by measuring the scraped area alteration because
of cell migration using ImageJ software. At least three independent experiments were conducted.
2.10. Statistical Analysis
Results are shown as means ± SD. Statistical analysis was performed using JMP 14.0 (SAS, Cary,
NC, USA) by using two-way analysis of variance (ANOVA) or chi-square test, where appropriate.
For descriptive statistics, continuous variables will be described as mean and standard deviation or
median and interquartile range for highly skewed biological variables (i.e., alanine and aspartate
aminotransferases (AST, ALT)). Variables with skewed distributions were logarithmically transformed
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before analyses. Analyses were performed by fitting data to generalized linear regression models.
General linear models were fit to examine continuous traits. Independent histological and biochemical
variables associated with miRNA expression in mice fed standard or MCD diet were assessed by
multivariate logistic regression analysis, and were adjusted for the confounders specified in the Results
section. Correlations were assessed by bivariate analysis or multivariate analyses after adjustment for
confounding factors. p-values < 0.05 (two-tailed) were considered significant.
3. Results
3.1. Hepatic Stellate Cells Isolated from InsR+/−Mice Show a Distinctive Pattern of miRNA Expression
To investigate which miRNAs were deregulated in the context of IR, we isolated HSCs from wt
and InsR+/−mice that showed an impairment in insulin signaling (Figure S1). Then, we performed a
gene expression differential analysis of the whole transcriptome of InsR+/− vs. wt HSCs by RNAseq.
We sequenced four replicates for each condition obtained from 40 to 61 million reads across the
samples with an average percentage of uniquely mapped reads of 72% ± 11% (Table S3). We found 36
differentially expressed miRNAs, 18 being down-regulated and 18 over-expressed in InsR+/− cells
(p < 0.05 vs. HSCs wt). Downregulated miRNAs included miR-1191, miR-3089, miR-101, miR-148a,
miR-1945, miR-30p, miR-5125, miR-3109, miR-3123, miR-138-2, miR-3058, miR-199a-1, miR-185,
miR-3094, miR-5129, miR-154, miR-1934, and miR-291a, whereas those upregulated were miR-103-1,
miR-132, miR-15a/b, miR-181b-2, miR-1932, miR-218-1, miR-24-2, miR-34b, miR-28, miR-361, miR-574,
miR-1983, miR-1907, miR-342, miR-5104, miR-27b, and miR-145 (Figure 1A). Pathway-enriched analysis
revealed that deregulated miRNAs were involved in cellular response to endotoxins and molecules
of bacterial origin (p = 2.8e−5; q * = 2.0e−4, * Benjamini-corrected vs. wt HSCs), response to oxygen
levels (p = 4.5e−10; q * = 1.3e−8, *Benjamini-corrected vs. wt HSCs), positive regulation of angiogenesis
and proliferation (p = 5.5e−2; q * = 1.6e−1, * Benjiamini-corrected vs. wt HSCs), and lipid metabolism
(p = 9.6e−3; q * = 7.2e−2, * Benjiamini-corrected vs. wt HSCs).
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Figure 1. Hepatic stellate cells isolated from insulin receptor (InsR)+/− mice showed a distinctive
patterns of microRNA (miRNA) expression. Heatmap was generated considering only specific m RNAs
differentially expressed between InsR+/− and wild-type (wt) (InsR+/+) hepatic tellate cells (HSCs)
(n = 4/group). We defined differentially expressed genes (DEGs), those with a p-value corrected (FDR)
lower than 0.1 (as DESeq2 default) and with a absolute fold-chang greater than 1.5. Red shading
indicat s induction and green shading indicates repression relative to the average levels of each miRNA
across all samples (A). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways wer enriched for
differ ntially expressed miRNAs in InsR+/− compared to wt HSCs by RNA-seq analy is. The statistical
significance level (p-value) was negative 10-based log tra s-formed (B).
As an independent approach, we also performed the enrichment analysis using KEGG gene
sets, resulting in very similar processes, such as enrichment of miRNAs involved in proliferation and
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cancer (p = 7.1e−11; q * = 7.1e−11, * Benjiamini-corrected vs. wt HSCs), particularly in neoplastic cell
transformation (Figure 1B). These data suggest that insulin-resistant HSCs displayed a peculiar pattern
of miRNA expression that may predispose to HSCs proliferation, possibly inducing more advanced
liver damage than their wt counterpart.
3.2. Differentially Expressed Hepatic miRNAs in InsR+/−Mice
To confirm the potential involvement of the differentially expressed miRNAs in IR-induced
liver injury and to explore their impact on hepatic fibrosis, we also analyzed the expression of those
miRNAs selected by RNAseq analysis to induce NASH in livers resected from InsR+/− and control
mice challenged with regular or MCD diet for 6 weeks. Biochemical features of mice fed standard or
MCD diet are shown in Table S2. We found that circulating alanine and aspartate aminotransferases
(ALT, AST) were not increased in InsR+/−mice compared to wt fed an MCD diet, resembling what has
been observed in IR- patients with type 2 diabetes (IR-T2D) with advanced fibrosis [20–22]. Despite
similar body weight, fasting insulin and HOMA-IR were increased in InsR+/− mice, which also
displayed enhanced hepatic Forkhead box protein O1 (FoxO1) protein expression, independently of
diet administration [9]. In addition, InsR+/−mice fed an MCD diet exacerbated hepatic IR, further
accumulating FoxO1 and impairing glucose metabolism. However, they preserved the activation of de
novo lipogenesis and developed excessive hepatic fat accumulation, resembling the clinical situation
observed in IR patients [9].
Indeed, InsR+/−mice fed an MCD developed a more severe hepatic steatosis and fibrosis (p < 0.01
vs. MCD diet-fed wt mice Figure 2A, Table S2), thus supporting the role of IR in NAFLD onset and in
increasing fibrosis deposition [8].
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Figure 2. Differentially expressed hepatic miRNAs in InsR+/−mice. Hematoxylin and eosin (H&E)
staining of hepatic specimens from wt and InsR+/− fed standard (SD) or methionine choline deficient
(MCD) diet (n = 10 mice/group). Original magnification: 200× (A, upper panels). Hepatic Sirius Red
staining in InsR+/− and wt mice fed an MCD diet for 6 weeks (A, lower panels). Hepatic miR-34b-3p,
miR-30p-3p, miR-3109-5p, miR-101-3p, and miR-138-2-3p expressions were evaluated by qRT-PCR in
lysates from total livers from wt (InsR+/+) and InsR+/−mice fed either an SD or MCD diet. Data were
normalized for hsa-miR-361-5p, hsa-miR-186-5p, hsa-miR-26a-5p, hsa-miR-191-5p, hsa-miR-451-5p,
and hsa-miR-423-5p average expression (n = 10 mice/group; * p < 0.05, ** p < 0.01) (B).
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Among the 36 miRNAs assessed, we found that miR-101-3p, miR-34b-3p, miR-30p-3p, miR-3109-5p,
and miR-138-2-3p were differentially expressed in the liver of InsR+/−mice compared to wt (p < 0.05
vs wt). miR-101-3p, miR-34b-3p, and miR-30p-3p were downregulated in InsR+/− mice, whereas
miR-3109-5p and miR-138-2-3p were upregulated (p< 0.01; p< 0.05; p= 0.07, respectively; Table 1). At the
multivariate analysis, applying a generalized linear model, miR-34b-3p, miR-30p-3p, miR-3109-5p,
and miR-101-3p were strongly associated with the InsR+/− genotype after the adjustment for the
administration of the MCD diet, whereas the association between miR-138-2-3p and InsR+/− genotype
was not significant (p = 0.07; Table 1).
Table 1. Independent predictors of hepatic miRNA levels in wt and InsR+/−mice fed a standard or
MCD diet.
miRNAs
InsR+/− Genotype MCD Diet Interaction (InsR+/− * MCD)
β 95% CI p * β 95% CI p * β 95% CI p *
miR-34b-3p −1.71 −2.54 to −0.89 0.0001 −0.23 −1.06 to 0.59 0.57 −0.41 −0.24 to 0.41 0.32
miR-101b-3p 0.13 −0.21 to −0.05 0.0009 −0.15 −0.23 to −0.07 0.0002 −0.15 −0.23 to −0.08 0.0001
miR-30p-3p −0.28 −0.55 to −0.02 0.03 0.17 −0.09 to 0.44 0.19 0.33 0.06 to 0.59 0.01
miR-3109-5p 0.92 0.02 to 1.84 0.04 0.29 −0.61 to 1.20 0.51 −0.81 −1.71 to 0.09 0.07
miR-138-2-3p 0.68 −0.07 to 1.43 0.07 0.47 −0.28 to 1.22 0.22 0.91 0.15 to 1.66 0.02
* At multivariate generalized linear models adjusted for MCD diet or InsR+/− genotype shown in the table.
Moreover, we also tested the interaction between MCD diet and InsR+/− genotype. miR-101-3p,
miR-30p-3p, and miR-138-2 displayed an additive effect of MCD diet and InsR+/− genotype (p < 0.05,
Figure 2B, Table 1). Specifically, miR-101-3p showed the stricter correlation to MCD and InsR+/−
genotype and the additive effect was even more significant (Table 1).
Then, we assessed the association between the histological features of liver damage evaluated by
using Kleiner score and the hepatic miRNA expressions. In the multivariate generalized linear model
analysis comparing wt and InsR+/−mice fed a standard or MCD diet, we found a significant negative
correlation between miR-34b-3p expression and the presence of histological steatosis (beta: −2.20; CI:
−3.71 to −0.66; p = 0.006), lobular inflammation (beta: −2.50; CI: −4.30 to −0.66; p =0.009), and NAS
score (beta: −1.41; CI: −2.30 to −0.51; p = 0.003), suggesting that its downregulation is involved in
early stages of NAFLD (Table 2). Conversely, miR-138-2-3p was only associated with the end stages of
liver disease, showing a positive correlation with the presence of fibrosis (beta: 1.37; CI: −0.03 to 2.77;
p = 0.05), as shown in Table 2. Consistently, miR-34b-3p was inversely correlated with intrahepatic
triglyceride content (p = 0.02; Figure S2A), supporting its steatogenic role, whereas miR-138-2-3p was
positively correlated with hydroxyproline content (p = 0.001; Figure S2B) and Red Sirius positive areas
(p = 0.03; Figure S2C), thus confirming its involvement in fibrosis development.
Table 2. Histological variables associated with hepatic miRNA expression at multivariate generalized
linear model analysis in wt and InsR+/−mice fed a standard or MCD diet.
Steatosis Lobular Inflammation Fibrosis NAS
β 95% CI p * β 95% CI p * β 95% CI p * β 95% CI p *
miR-34b-3p −2.20 −3.71 to −0.66 0.006 −2.50 −4.30 to −0.66 0.009 −0.54 −2.13 to 1.03 0.49 −1.41 −2.30 to −0.51 0.003
miR-101-3p −0.16 −0.33 to 0.001 0.05 −0.21 −0.41 to −0.02 0.03 −0.30 −0.44 to −0.15 0.0001 −0.12 −0.21 to −0.01 0.02
miR-30p-3p −0.33 −0.86 to 0.19 0.22 0.26 −0.37 to 0.90 0.41 −0.19 −0.71 to 0.32 0.45 −0.05 −0.37 to 0.27 0.74
miR-3109-5p 0.23 −1.47 to 1.95 0.78 −0.52 −3.52 to 0.47 0.13 −0.16 −1.83 to 1.5 0.84 −0.30 −1.32 to 0.72 0.56
miR-138-2-3p 0.19 1.30 to 1.69 0.79 0.78 −0.98 to 2.54 0.34 1.37 −0.03 to 2.77 0.05 0.27 −0.62 to 1.16 0.55
* At multivariate generalized linear models adjusted for the presence of MCD diet and InsR+/− genotype.
Interestingly, only miR-101-3p was found to be significantly related to all spectra of liver damage
from steatosis (beta: −0.16; CI: −0.33 to 0.001; p = 0.05), to lobular inflammation (beta: −0.21; CI: −0.41
to −0.02; p = 0.03), and fibrosis (beta: −0.30; CI: −0.44 to −0.15; p = 0.0001) (Table 2). Indeed, miR-101-3p
showed a significant trend with all parameters analyzed, negatively correlating with intrahepatic
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triglycerides (p < 0.0001; Figure 3A), hydroxyproline concentration (p < 0.0001; Figure 3B), and Red
Sirius positive areas (p < 0.0001; Figure 3C).Nutrients 2019, 11, x FOR PEER REVIEW 8 of 19 
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Figure 3. Hepatic miR-101-3p downregulation was related to all spectra of liver damage.
Correlation analyses between miR-101-3p expression and intrahepatic triglyceride (TG) content
(%) (A), hydroxyproline (µg/mg) concentration, representative of collagen deposition (B), and Red
Sirius positive area, quantified by ImageJ software in 10 random non-overlapping fields for each
mouse (C). miR-101-3p expression was evaluated by qRT-PCR in lysates from total livers from
wt (InsR+/+) and InsR+/− mice fed either an SD or MCD diet (n = 10 mice/group). Data were
normalized for hsa-miR-361-5p, hsa-miR-186-5p, hsa-miR-26a-5p, hsa-miR-191-5p, hsa-miR-451-5p,
and hsa-miR-423-5p average expression.
With regard to miR-30p-3p and miR-3109-5p, we did not find any association between them and
the histological features.
Overall, these data suggest that miR-34b-3p, miR-138-2-3p, and miR-101-3p could specifically
profile the stage of liver injury related to IR. In particular, miR-101-3p exhibited the strongest interaction
between MCD and IR, showing a lower expression during the co-existence of genetic IR and diet-induced
liver damage.
3.3. Pathway-Enriched Analysis of Differentially Expressed miRNAs in HSCs
Bioinformatic analysis was performed to gain insight into the functional impact of targeted genes
of miR-101-3p. By using the softwa e TargetScan, we obtained a list of the predicted t rgets hat may
be potentially involved in metabolic dise s s and liver damage in the context of IR.
Analyzing miR-101-3p targets, we obtaine a total of 720 g nes from predicted databases involved
in cellular response to insulin stimulus, insuli signaling activation, inositol phospha metaboli m,
i su in secretion, IR, and regulatio of lipolysis in adipocyte , as well as ECM orga iza ion, epithelial
to mesenchymal tran ition, cell adhesion, proliferation, and differe ti tion. The d ta obtained from
GO analysis is summarized in Table S5, d the most significantly enriched biolog cal processes
were exhibited according to the count of genes involved. Pathways fro KEGG were significantly
enriched in insulin signaling activation, inosit l metabolism, and cancer evelopment (Figure 4A;
Table S6). These findi gs further rei forced the results observed in our model of IR-NASH, supporting
the im lication of miR-101-3p downregulation the dev lopment and wo sening of liver damage
aggravated by the presence of en t c IR.
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Figure 4. Hepatic stellate cells (HSCs) and hepatic miR-101-3p downregulation contributed to IR. KEGG
pathways enriched for miR-101-3p targeted genes by DAVID. The statistical significance level (p-value)
was negative 10-based log trans-formed (A). Correlation analyses between miR-101-3p expression
evaluated by RNAseq in wt and InsR+/− HSCs and insulin receptor (InsR) expression (B), insulin-like
growth factor 1 receptor (Igfr1) (C), and Igfr2 (D). Correlation analyses between miR-101-3p expression
assessed by qRT-PCR in total livers from wt and InsR+/−mice fed either standard (SD) or MCD diets
(n = 10 mice/group) and adipose tissue expression of resistin. Resistin mRNA levels were evaluated by
qRT-PCR and normalized for beta-actin as housekeeping (n = 10/group) (E).
Then, we focused on genes involved in insulin signaling and we found that miR-101-3p expression
positively correlated with mRNA levels of InsR and insulin-like growth factor receptor 1 and 2 (Igfr1/2)
in HSCs analyzed by RNAseq (p < 0.05; Figure 4B–D). Moreover, hepatic miR-101-3p expression was
inversely related to the adipose tissue expression of Resistin in wt and InsR+/− ice fed either a
standard or MCD diet (p < 0.05; Figure 4E). Indeed, lower levels of miR-101-3p were associated with
higher resistin, an adipokine that promotes IR and inflammation at a hepatic level, secretion into the
blood flow in t and InsR+/−mice fed either a standard or MCD diet, suggesting that its alteration
may contribute to IR by regulating adipose tissue-specific adipokines, (p < 0.05; Figure 4E).
3.4. miR-101-3p a d Pathway-Related Targets Involved in Fibrosis and Cell Proliferation in HSCs
Since the hepatic expression of miR-101-3p was markedly decreased in InsR+/−mice fed MCD
(Figure 2B), we next focused on better understanding its impact on fibrogenesis promotion and HCC
development by evaluating the expression of miR-101-3p putative mRNA targets, previously predicted
by bioinformatic analysis and proven by experimental evidence [14] in InsR+/−HSCs compared to
wt by exploiting RNAseq data. As expected, markers of liver fibrosis, angiogenesis, proliferation,
cell cycle progression, invasion, and migration such dual specificity protein phosphatase 1 (Dusp1),
Mcl-1, mammalian target of rapamycin (mTor), vascular endothelial growth factor (Vegf-c), and c-Fos
were inversely correlated with miR-101-3p levels in HSCs (p < 0.05; Figure 5A–C and Figure S3A,B),
showing higher expression in HSCs InsR+/− compared to wt (p < 0.05 or p < 0.01 vs. wt HSCs;
Figure 5A–C and Figure S3A,B). Furthermore, even zonula occludens-1 (ZO-1), which has cell adhesion
properties, was positively correlated to the expression of miR-101-3p in HSCs (p < 0.01; Figure S3C)
and it displayed lower levels in InsR+/− HSCs compared to wt ones (p < 0.01 vs. wt HSCs; Figure
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S3C), supporting the fact that the down-regulation of miR-101-3p observed during IR may predispose
to advanced fibrosis and exert pro-carcinogenic effects.
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Figure 5. Predicted gene targets of miR101b-3p were up-regulated in InsR+/− HSCs. Correlation
analyses between miR-101-3p analyzed in wt and InsR+/−HSCs and dual specificity protein phosphatase
1 (Dusp1). Dusp1 mRNA levels in wt and InsR+/−HSCs by RNAseq (A). Correlation analyses between
miR-101-3p assessed in wt and InsR+/− HSCs and Mcl-1. Mcl-1 mRNA levels in wt and InsR+/− HSCs
by RNAseq (B). Correlation analyses between miR-101-3p analyzed in wt and InsR+/− HSCs and
mammalian target of rapamycin (mTor). mTor mRNA levels in wt and InsR+/− HSCs by RNAseq
(C) (n = 4/group; * p < 0.05 vs. wt (InsR+/+) HSCs).
Finally, to confirm the pleiotropic downmodulation of miR-101-3p during IR, we isolated wt and
InsR+/− primary mouse hepatocytes and HSCs. Next, we assessed miR-101-3p expression by qRT-PCR
in the presence of a high concentration of insulin (0.33 µM) for 6 h and/or PAOA (0.25 mM) for 24 h,
which mimicked hyperinsulinemia and diet-induced fat accumulation, respectively. We highlighted
that miR-101-3p was expressed ~80% less in HSCs than hepatocytes (p< 0.01 vs. hepatocytes, Figure 6A)
and that both insulin-resistant cell types displayed lower expression of miR-101-3p compared to their
wt counterpart (p < 0.05 vs. wt hepatocytes or p < 0.05 vs. wt HSCs; Figure 6A). These data suggest that
the ubiquitously reduction of miR-101-3p in IR may exert an impact on different cell types, possibly
explaining its correlation with all spectra of liver damage.
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insulin (0.33 µM, for 6 h) alone or in a c mbination with palmitic (PA) and oleic (OA) a ids (ratio 1:2, final
concentration 0.25 mM, for 24 h) (A). Expression of miR-101-3p in primary mouse hepatocytes (Hep)
and HSCs, and in human immortalized hepatom cells (HepG2) and HSCs (LX-2) (B). Expression of
miR-101-3p in HepG2 and LX-2, exposed to insulin (0.33 µM, for 6 h) (C). The expression was evaluated
by qRT-PCR and normalized for hsa-miR-361-5p, hsa-miR-186-5p, hsa-miR-26a-5p, hsa-miR-191-5p,
hsa-miR-451-5p, and hsa-miR-423-5p average expression and expressed as fold increase compared to
untreated wt (InsR+/+) hepatocytes or HepG2 cells (arbitrary units—AU). At least three independent
experiments were conducted (* p < 0.05, ** p < 0.01).
In addition, insulin upregulated miR-101-3p in both wt hepatocytes and HSCs (p < 0.05 vs.
untreated wt hepatocytes or HSCs; Figure 6A) and downregulated collagen (Col1A1) and α-sma
mRNA levels—markers of fibrogenesis—in HSCs (p < 0.05 vs. untreated wt HSCs; Figure S4A).
However, the effect of insulin on miR-101-3p was lost in InsR+/− HSCs (vs. untreated InsR+/−
HSCs; Figure 6A), which in turn showed a higher expression of Col1A1 and α-sma (p < 0.05 vs.
untreated InsR+/−HSCs; Figure S4A), further corroborating the hypothesis that miR-101-3p expression
is ediated by the presence of he InsR. Inde d, the haploinsufficiency of InsR negatively regulated
miR-101-3p expression, leading to fibrotic marker induction.
Conversely, the exposure to fatty acids dramatically hampered the expression of miR-101-3p in
both wt and InsR+/− hepatocytes and HSCs (p < 0.01 vs. untreated wt hepatocytes and p < 0.01 vs.
untreated wt HSCs; Figure 6A), reaching lower levels in InsR+/− cells co-stimulated with insulin and
PAOA (p < 0.01 vs. InsR+/− PAOA hepatocytes or p < 0.05 vs. wt PAOA HSCs; Figure 6A).
It could be speculated that the marked downregulation of miR-101-3p observed in InsR+/−
hepatocytes exposed to a combination of insulin and PAOA may resemble the decreased expression of
this miRNA occurring in total liver in the context of IR and MCD interaction.
3.5. miR-101-3p was Down-Regulated in HepG2 and LX-2 Cells
Given the association between miR-101-3p and advanced liver injuries observed in our IR-NASH
model, we ev luated the expression of miR-101-3p in immortalized cell lines by using hepatoma
(HepG2) and hepatic stellates cells (LX-2), n vitro m dels commonly used to study liver fibrosis
and canc r.
The expression of miR-101-3p was significantly downmodulated in both HepG2 and LX-2
compared to primary mouse hepatocytes and HSCs (p < 0.01 vs. primary cells; Figure 6B), thus
representing a reliable model for studying the effects of miR-101-3p restoration in the presence of
preserved insulin signaling. Moreover, in keeping with the previous results, the exposure to insulin
(0.33 µM) increased the expression of miR-101-3p in both cell types (p < 0.05 vs. untreated cells;
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Figure 6C) and hampered, in turn, COL1A1 and α-SMA expression (p < 0.05 vs. untreated LX-2;
Figure S4B), supporting the hypothesis that insulin signaling activation through insulin receptor may
sustain miR-101-3p expression.
Therefore, we exploited these two cell lines characterized by rapid growth and low expression
of miR-101-3p to further investigate the effect of miR-101-3p restoration on hepatocytes and HSC
proliferation and invasiveness.
3.6. Overexpression of miR-101-3p Inhibited HepG2 and LX-2 Cell Proliferation and Migration
To deeply investigate the functional role of miR-101-3p in the promotion of liver fibrosis and
hepatocarcinogenesis, we transfected HepG2 and LX-2 cell lines with 25 nM miR-101-3p mimic or
with 25 nM miR-1 mimic positive control for 24 h. To evaluate the efficiency of our experimental
setting, we first analyzed the expression of miR-1 as a positive control and found that miR-1-3p
levels were dramatically increased in HepG2 and LX-2 cells (p < 0.01 vs. control and vs. miR-101-3p
mimic; Figure S5A), as expected. Secondly, transient transfection with miR-101-3p mimic strongly
enhanced the expression of miR-101-3p in both HepG2 and LX-2 cells, inducing a more than 500-fold
higher expression of mature miR-101-3p compared to cells transfected with lipofectamine alone
(negative control) or with miR-1 positive control (p < 0.01 vs. control and vs. miR-1 mimic, Figure 7A).
Consistently, the expression of miR-101-3p target genes, DUSP1, MCL-1 and mTOR, was significantly
downregulated in HepG2 and LX-2 cells treated with miR-101-3p mimic rather than negative controls
(p < 0.05 or p < 0.01 vs. control; Figure 7B–D) or miR-1 positive control (p < 0.05 or p < 0.01 vs. miR-1
mimic; Figure 7B–D). Moreover, miR-101-3p induction hampered the expression of pro-fibrotic genes,
such as TGF-β in both HepG2 and LX-2 cells (p < 0.05 vs. control and p < 0.05 vs. miR-1 mimic;
Figure 8A) and α-SMA in LX-2 (p < 0.05 vs. control and vs. miR-1 mimic; Figure 8B), a marker of HSC
activation. In addition, miR-101-3p overexpression markedly reduced BCL-2, BCL-XL and cJUN, which
are markers of proliferation in both cell types (p < 0.05 vs. control and vs. miR-1 mimic; Figure 8C–E),
thus supporting the ability of miR-101-3p to negatively regulate cell proliferation.
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Figure 7. miR101b-3p mimic effectively increased miR-101-3p expression in HepG2 and LX-2 cells.
Expression of miR-101-3p by qRT-PCR in HepG2 and LX-2 cells transfected for 24 h with 25 nM
miR-101-3p mimic, 25 nM miR-1 mimic positive control (miR-1 mimic), or lipofectamine alone
(Ctrl). Data were normalized for hsa-miR-361-5p, hsa-miR-186-5p, hsa-miR-26a-5p, hsa-miR-191-5p,
hsa-miR-451-5p, and hsa-miR-423-5p average expression and expressed as f ld increase compared to Ctrl
(arbitrary units—AU). At least thre indep ndent experiments were conducted (* p < 0.05, ** p < 0.01)
(A). DUSP1 (B), MCL-1 (C), and mTOR (D) mRNA levels were evaluated by qRT-PCR in HepG2 and
LX-2 cells transfected for 24 h with 25 nM iR-101-3p mimic, 25 nM iR-1 mimic positive control
(miR-1 mimic), or lipofectamine alone (Ctrl). Data were normalized for beta-actin as housekeeping.
At least three independent experiments were conducted (* p < 0.05, ** p < 0.01).
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Figure 8. miR101b-3p mimic down-regulated genes involved in fibrosis and cell proliferation in HepG2
and LX-2 cells. TGF-β (A), α-SMA (B), BCL-2 (C), BCL-XL (D), and cJUN (E) mRNA levels were
evaluated by qRT-PCR in HepG2 and LX-2 cells transfected for 24 h 25nM miR-101-3p mimic or 25nM
miR-1 mimic positive control (miR-1 mimic) or lipofectami e alone (Ctrl). Data were normalized for
beta-actin as housekeep ng and ar expressed as fold increase compared to Ctrl (arbitrary units—AU).
At l ast three indepe dent experim nts were conduct d (* p < 0.05, ** p < 0.01).
In line with the reduction of genes involved in cell cycle progression, the enforced expression of
miR-101-3p significantly inhibited proliferation in HepG2 and LX-2 mimic transfection group compared
to negative and positive miRNA mimic controls at 24, 48, and 72 h, as assessed using MTS assay
(p < 0.01 vs. control and vs. miR-1 mimic; Figure 9A,B).
According to the reduced expression of miR-101-3p, even the low-proliferating primary InsR+/−
HSC showed an enhanced rate of proliferation compared to wt forms at 48 and 72 h (p < 0.01 vs. wt
HSCs; Figure S5B).
Finally, given th impact of cellular migrati n in liv r fibrosis, cancer development, and metastasis,
we next sought to evaluate the effect of miR-101-3p overexpression on the ability of migration of HepG2
and LX-2 cells by exploiting a wound-healing assay that revealed that miR-101-3p transfected cells
healed the wound more slowly than controls (Figure 9C,D). Hence, we could speculate that miR-101-3p
induction may contribute to prevent hepatic fibrosis development and progression to advanced stages
of liver disease.
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25 nM iR-101-3p mimic, 25nM miR-1 mimic pos tive control (miR-1 mimic), or ipofectamine alone
(Ctrl). MTS absorba ces at 490 nm were recorded at 0, 4, 48, and 72 h. Data ar expressed as fold
increase compared to Ctrl (arbitrary units—AU) (** p < 0.01 vs. Ctrl). Wound healing assay for HepG2
C and LX-2 (D). Repres ntative i ages of the mig ated cells were taken 0 nd 24 h after the scratch
formation. HepG2 and LX-2 were pre-treated with 25 nM iR-101-3p imic, 25 nM miR-1 mimic
positive control (miR-1 mimic), or lipofectamine alone (Ctrl) 24 h before the scratch. At l ast three
independent experiments were conducted.
4. Discussion
In the present study, we explored the mechanisms through which epigenetics and environmental
factors interact to promote progressive NAFLD in the context of IR. To this end, IR was induced in
mice by haploinsufficiency for InsR (InsR+/−) [13–15], determining an impairment of hepatic insulin
signaling that best recapitulates what is observed in NAFLD patients [8,23]. Conversely, to model
fibrogenic NASH we exploited the MCD diet, which impairs phospholipid metabolism without
altering IR [16]. This allowed the evaluation of the independent influence of IR and NASH on
miRNA deregulation.
Therefore, we assessed the expression of miRNAs through different approaches, with the goal
of studying the regulation of cell-to-cell communication between hepatocytes and HSCs that occurs
during fibrogenesis, and to reveal candidate non-invasive biomarkers for an accurate profiling of the
different stages of the liver injury, possibly enabling the early and non-invasive diagnosis and the
clinical monitoring of the disease progression.
Firstly, we examined the miRNA signature in InsR+/− HSCs, which are characterized by an
impaired insulin signaling, by analyzing the whole transcriptome, revealing 36 differentially expressed
miRNAs compared to wt cells. These deregulated miRNAs were mainly involved in cell proliferation
and cancer onset, probably profiling a peculiar pattern of miRNA expression that may orchestrate liver
damage progression towards fibrosis and cancer development in IR conditions [4,24–27].
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Secondly, we evaluated whether the miRNAs differentially expressed in insulin-resistant HSCs
could impact on NAFLD-related fibrosis by using an experimental model of IR-NASH that develops
hepatic IR reminiscent of that observed in patients with accumulation of FoxO1 and impairment
of glucose metabolism but preserved activation of de novo lipogenesis [8,9]. This model does not
completely reproduce the human NAFLD because the MCD diet induced weight loss and hypoglycemia,
although it has been largely used to study intrahepatic events related to NASH because it replicates the
histological spectrum of NAFLD from simple steatosis to advanced fibrosis [28]. However, as previously
demonstrated by our group [8], this model of genetic IR was characterized by higher insulin levels
and HOMA-IR, and was associated with increased steatosis and liver fibrosis accumulation, even
independently of hepatic inflammation. Nonetheless, circulating transaminases were not increased
in InsR+/−mice compared to wt fed an MCD diet resembling what has been observed in IR patients
with type 2 diabetes (IR-T2D) and advanced fibrosis [20–22]. Indeed, it has been observed that
a subgroup of type 2 diabetes (T2D) patients develop advanced fibrosis with normal enzymes
even in the absence of NASH [20–22], thereby suggesting that IR can promote fibrosis deposition
independently of inflammation, representing a complementary pathway, leading to advanced liver
fibrosis. Moreover, genetic variants that impair InsR signaling favor fibrosis development in NAFLD [8].
We previously proposed that the mechanism whereby IR aggravates fibrosis seems to not be related
to increased ECM deposition, but even more to reduced ECM turnover as highlighted by lower
expression of metalloproteinases (MMPs) and enhanced production in enzymes involved in collagen
crosslinking and pro-fibrogenic processes [9,29]. Therefore, we evaluated the hepatic expression
of the 36 candidate miRNAs in InsR+/− mice fed MCD for 6 weeks and we demonstrated that
miR-34b-3p, miR-138-2-3p, and miR-101-3p were strongly associated with InsR+/− genotype and
MCD. Peculiarly, lower expression of miR-101-3p was closely associated with the co-existence of
genetic IR and diet-induced liver damage, mirroring the mechanisms underlying epigenetic and
environmental interplay. The main finding of this study is that among these three miRNAs, only the
hepatic expression of miR-101-3p was related to all histological spectra of liver damage from steatosis
to lobular inflammation and fibrosis in InsR+/−mice.
Pathway-enriched analyses of predicted target genes highlighted that miR-101-3p was mainly
involved in metabolic processes such as inositol phosphate metabolism, insulin signaling activation,
insulin secretion, IR, and regulation of lipolysis in adipocytes. According to these findings, in HSCs,
miR-101-3p positively correlated with InsR and Igfr1/2. Furthermore, the reduced hepatic expression
of miR-101-3p in InsR+/− mice influenced adipose tissue expression of resistin, an adipokine that
promotes IR and propagates inflammation in the liver, thus contributing to IR through the regulation
of key mediators of insulin signaling.
The link between miR-101 and insulin-related diseases has been reported in several preclinical
and clinical studies. Indeed, miR-101 has been described in metabolic and autoimmune disorders,
such as type 1 diabetes (T1D) and T2D, which have in common the loss of functional pancreatic
β-cells. In particular, the pathogenesis of T1D is a complex mechanism involving the production
of islet autoantibodies, genetics, and environmental factors. Zheng Y. and colleagues found that
miR-101a is enriched in pancreatic cells and participates in β-cell dysfunction by decreasing the
expression of antiapoptotic Bcl-2 and reducing pancreatic insulin secretion [30]. Higher circulating
levels of miR-101-3p have also been reported to be associated with early-onset of T1D and T2D [31,32].
Therefore, the tissue expression of several miRNAs could be a consequence of a dynamic regulation of
the rate of miRNAs produced and released into the circulation [4].
miR-101-3p was downmodulated in insulin-resistant primary hepatocytes and HSCs and even
more in both InsR+/− cell types treated with insulin and fatty acid overload, which resembled what
was observed in the total liver in the context of IR and MCD interaction. Conversely, insulin stimulated
miR-101-3p expression in both wt hepatocytes and HSCs, but not in InsR+/− cells, suggesting that its
expression was mediated by the presence of the insulin receptor. In line with miR-101-3p induction,
collagen and α-sma levels were hampered in wt HSCs after insulin exposure. Conversely, markers of
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fibrogenesis were upregulated in InsR+/− HSCs, supporting that the impairment of insulin signaling
may dampen miR-101-3p expression and favor fibrosis development. In addition, we confirmed this
evidence also in HepG2 and LX-2 cells exposed to insulin. Similarly, even Zhu et al. demonstrated
that inhibition of insulin signaling reduced miR-101 levels and enhanced its target genes in RAW264.7
macrophages [33].
Overall, our findings demonstrate that miR-101-3p downregulation was more strongly associated
with hepatic injury when both IR and environmental stimuli, such as diet, coexisted in IR-NASH and
in vitro models. Pathway analyses of predicted target genes also revealed an enrichment in endotoxins
response, ECM deposition and organization, epithelial mesenchymal transition, cell adhesion, and
TGF-β signaling, as well as cell proliferation and differentiation, possibly through Dusp1, mTOR, Mcl-1,
and many others, as previously demonstrated [25,33,34]. Consistently, in insulin-resistant HSCs the
expression of these genes was strongly enhanced, supporting the hypothesis that downregulation of
miR-101-3p observed during IR may predispose to more advanced fibrosis and exert pro-carcinogenic
effects. Indeed, several studies demonstrated that HSC activation and hepatic fibrogenesis is influenced
by miR-101-3p downregulation, speculating that its restoration may ameliorate hepatic fibrosis [35].
Nevertheless, these studies showed that miR-101 was dampened in both hepatocytes and HSCs
during CCl4-induced liver fibrosis as a consequence of transcriptional regulation of miR-101 by
TGF-β signaling. The downregulation of miR-101 has been identified even in cardiac and pulmonary
fibrosis [36,37]. Collectively, these findings strengthen the concept that deregulation of miR-101-3p is
closely intertwined with fibrotic processes in different tissues.
Finally, to better explore the role of miR-101-3p in hepatic fibrosis and cell proliferation, we managed
to overexpress it in human hepatoma cell lines (HepG2) and in HSCs (LX-2). We preferred to use
immortalized cell lines because of their higher rate of proliferation and their ability to maintain
cell-specific features. As rapidly proliferating cells, both HepG2 and LX-2 showed lower levels of
miR-101-3p, as already reported by Hang Su et al. [38], compared with primary mouse hepatocytes
and HSCs, thus representing a reliable model to study the effects of miR-101-3p restoration.
Notably, we demonstrated that miR-101-3p overexpression significantly inhibited the cell growth
and exerted an impact on cellular migration and invasion in both hepatocytes and HSCs. Furthermore,
the InsR+/−HSCs displayed a higher proliferation rate compared to the wt ones, further supporting
the hypothesis that miR-101-3p downregulation promotes cell proliferation. In our study, the enhanced
expression of miR-101-3p inhibited pro-fibrotic genes (TGF-β and α-SMA) and the anti-apoptotic
genes BCL-2, BCL-XL, cJUN, DUSP1, MCL-1, and mTOR, possibly explaining the suppression of
proliferation rate and the escape from apoptosis. miR-101 has been described as one of the most
downregulated miRNAs in cancer-associated fibroblasts (CAFs), the main component of tumor stroma
that creates a micro-environment that favors cancer progression [39]. In these cells isolated from
lung tissue, the overexpression of miR-101 significantly impaired the ability of CAFs to stimulate
tumor cell proliferation, migration and invasion, and enhanced apoptosis. Furthermore, loss of
miR-101 promotes TGFβ1-induced epithelial mesenchymal transition process and the expression of
mesenchymal markers in hepatocytes. Recently, miR-101-3p has been reported as a potent tumor
suppressor in cancer development, progression, and therapy because it enhances doxorubicin-induced
cytotoxicity and impacts upon chemoresistance of cisplatin in HepG2 cells [40–42]. According to
our results, miR-101 downregulation was previously observed in multiple cancerous tissues, such
as lung, colon, liver, gastric, breast, ovary, and prostate [25,43–46] decreasing early when tumors are
poorly differentiated. Nonetheless, Li et al. [25] analyzed the data from The Cancer Genome Atlas
(TCGA) and demonstrated that miR-101-1 expression was lower in cancer than in non-tumor liver
tissues, and that this downregulation was also closely related to poor differentiation; high tumor,
node, and metastasis (TNM) classification; poor tumor stage; positive lymph node metastasis; high
alpha-fetoprotein; and poor overall survival in patients [47], assuming a great diagnostic and prognostic
value of HCC [25]. Moreover, circulating miR-101 plasma levels were dramatically reduced in distant
metastatic HCC patients and interestingly miRNA-based targeted therapy abrogated HCC growth in
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the liver, intrahepatic and distant metastasis to the lung, and mediastinum in an animal model of liver
cancer [47].
5. Conclusions
In conclusion, all these findings indicate that IR is associated with a distinctive miRNA signature
in both hepatocytes and HSCs, which may promote their proliferation and transdifferentiation.
Specifically, miR-101-3p downregulation may profile all stages of liver disease, promoting the hepatic
fibrosis in IR conditions by enhancing activation and survival of HSCs and predisposing to cancer
development, inducing anti-apoptotic gene expression. Further studies are needed to deeply investigate
the mechanisms linking IR and miR-101-3p in both early stages and progressive NAFLD with the goal
of considering miR-101 as a candidate non-invasive biomarker to early diagnose hepatic fibrosis onset
in NASH patients with IR.
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